EU Urges Sponsors To Assess COVID-19 Impact Before Starting New Trials
New Survey Shows Pandemic Is Negatively Impacting Patient Enrollment
Executive Summary
New EU guidance on managing clinical trials in the context of COVID-19 requires sponsors to critically assess the feasibility of starting a new clinical trial or including new participants in an ongoing trial. A separate survey indicates that patient willingness to participate in new trials has dramatically declined due to the pandemic.
You may also be interested in...
EU Allows More Flexibility In Managing Trials During COVID-19
The EU has issued revised guidance to ensure that clinical trials can continue taking place during the COVID-19 pandemic.
Parexel Execs On How To Adapt Clinical Studies Amid The Pandemic
Parexel executives tell Scrip about the company’s efforts in tandem with sponsors to navigate the challenging clinical research environment amid COVID-19. A renewed interest for decentralized trials or hybrid approaches and the use of remote monitoring and telehealth visits to keep studies moving are some of the key initiatives.
COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.